Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance

NCT03521596 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.

NCT NCT03521596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03521596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance
Lead sponsor
Fondazione Italiana Linfomi - ETS
Phase
Observational
Overall status
Completed
Start date
August 28, 2018
Completion date
October 2, 2025
Enrollment
300 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

waldenstrom macroglobulinemia